Metacrine Completes Dosing of First Cohort in Phase 1 Trial of MET409, a Novel Non-Bile Acid FXR Agonist
June 13, 2018 07:30 ET
|
Metacrine
SAN DIEGO, June 13, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today...
Metacrine Completes $65 Million Series C Financing
June 06, 2018 07:30 ET
|
Metacrine
SAN DIEGO, June 06, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today...
Metacrine to Present Role of FXR in Treating Inflammatory Bowel Disease at Digestive Disease Week 2018
May 31, 2018 16:05 ET
|
Metacrine
SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today...
Metacrine to Present at Jefferies 2018 Global Healthcare Conference
May 31, 2018 07:30 ET
|
Metacrine
SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today...
Metacrine Broadens Management Team with Two Key Hires
April 17, 2018 08:00 ET
|
Metacrine
SAN DIEGO, April 17, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today...
AXIM Biotech Reaches Preliminary Agreement for Distribution of CanChew and MedChew Products Throughout South Korea
April 03, 2018 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTCQB:AXIM), a world leader in cannabinoid research and development, today announced that it has...
Axim Biotechnologies Announces Phase IIa Trial Results Validating its Proprietary Cannabinoid Delivery Method for Treatment of Irritable Bowel Syndrome (IBS)
November 21, 2017 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Nov. 21, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced clinical trial results...
AXIM® Biotechnologies Secures Funding to Advance Clinical Trials and Bioequivalency Study
June 19, 2017 09:00 ET
|
AXIM Biotechnologies, Inc
NEW YORK, June 19, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the Company has...
AXIM Biotech Announces Enrolled Patients Begin Phase II Trial for the Treatment of Irritable Bowel Syndrome With CanChew Plus® Cannabidiol (CBD) Chewing Gum
March 07, 2017 09:00 ET
|
AXIM Biotechnologies, Inc
NEW YORK, March 07, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced enrollment of 40 patients...
AXIM® Biotech Enters IBS Clinical Trial for CanChew CBD Chewing Gum
January 18, 2017 09:00 ET
|
AXIM Biotechnologies, Inc
NEW YORK, Jan. 18, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, entered a clinical trial on treating...